Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer
暂无分享,去创建一个
T. Behl | S. Bungău | Aditi Sharma | Celia Vargas-De-la-Cruz | Haroon Khan | Shivam Yadav | L. Sharma | M. Anwer | Shouvik Kumar Nandy | Nazrana Payal | S. Nandy | Celia Vargas‐De‐La‐Cruz
[1] H. Abrahamse,et al. Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment , 2022, Cells.
[2] A. Valdiani,et al. Andrographis paniculata extract as an immunity modulator against cancer via telomerase inhibition , 2022, 3 Biotech.
[3] J. Sharifi‐Rad,et al. Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine , 2022, Cancer cell international.
[4] Dileep Kumar,et al. Exploring the structural and functional requirements of Phyto-compounds and their synthetic scaffolds as anticancer agents: medicinal chemistry perspective , 2022, Pharmacological Research - Modern Chinese Medicine.
[5] Kyu Bong Cho,et al. A Review of Natural Products for Prevention of Acute Kidney Injury , 2021, Medicina.
[6] I. S. Cogno,et al. Light-activated green drugs: How we can use them in photodynamic therapy and mass-produce them with biotechnological tools , 2021 .
[7] M. Bijak,et al. The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment , 2021, International journal of molecular sciences.
[8] Yang Ouyang,et al. Chalcone Derivatives: Role in Anticancer Therapy , 2021, Biomolecules.
[9] G. Zengin,et al. Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme , 2021, Cancers.
[10] S. Hua,et al. Perspectives and controversies regarding the use of natural products for the treatment of lung cancer , 2021, Cancer medicine.
[11] I. Heydari,et al. Association of Serum and Tumor Tissue microRNA Profile with Aggressiveness of Papillary Thyroid Carcinoma in an Iranian Population , 2021 .
[12] A. Daneshkhah,et al. Clinical effects of curcumin in enhancing cancer therapy: A systematic review , 2020, BMC Cancer.
[13] R. Derynck,et al. TGFβ biology in cancer progression and immunotherapy , 2020, Nature Reviews Clinical Oncology.
[14] N. Agarwal,et al. Advanced Prostate Cancer: Treatment Advances and Future Directions. , 2020, Trends in cancer.
[15] M. Vinceti,et al. Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? , 2020, Biochimica et biophysica acta. Molecular cell research.
[16] J. Humm,et al. Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma , 2020, PloS one.
[17] Y. Ghasemi,et al. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells , 2020, Cell & Bioscience.
[18] M. Morassi,et al. Late intracranial metastasis from adenoid-cystic carcinoma of the parotid gland: Imaging, histologic and molecular features. , 2020, Current problems in cancer.
[19] Hai-hua Luo,et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. , 2020, The Journal of clinical investigation.
[20] P. Limonta,et al. Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets , 2020, Cells.
[21] James X. Sun,et al. Principles of Targeted Therapy for Melanoma. , 2020, The Surgical clinics of North America.
[22] A. Onitilo,et al. Principles of Immunotherapy in Melanoma. , 2020, The Surgical clinics of North America.
[23] Marcus Krüger,et al. Multikinase Inhibitor Treatment in Thyroid Cancer , 2019, International journal of molecular sciences.
[24] Y. Kikushige. Pathophysiology of chronic lymphocytic leukemia and human B1 cell development , 2019, International Journal of Hematology.
[25] M. Cabanillas,et al. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. , 2019, Endocrine reviews.
[26] H. Gurney,et al. Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer , 2019, Asia-Pacific journal of clinical oncology.
[27] V. V. Padma,et al. The cytoprotective and anti-cancer potential of bisbenzylisoquinoline alkaloids from Nelumbo nucifera. , 2019, Current topics in medicinal chemistry.
[28] P. Vaupel,et al. NK cell-based therapeutics for lung cancer , 2019, Expert opinion on biological therapy.
[29] P. Marchetti,et al. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. , 2019, European journal of pharmacology.
[30] M. Gleave,et al. Towards precision oncology in advanced prostate cancer , 2019, Nature Reviews Urology.
[31] T. Habermann,et al. Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era , 2019, Leukemia & lymphoma.
[32] M. Zeng,et al. ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma , 2019, Oncogene.
[33] P. Queirolo,et al. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. , 2019, Seminars in cancer biology.
[34] P. Åman,et al. IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors , 2019, Cells.
[35] J. Molina,et al. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.
[36] M. R. Ruocco,et al. Metabolic flexibility in melanoma: a potential therapeutic target. , 2019, Seminars in cancer biology.
[37] M. Gertz,et al. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis , 2019, Expert review of clinical pharmacology.
[38] T. Ramachandra,et al. Phytochemical and Pharmacological Importance of Turmeric (Curcuma longa): A Review , 2019 .
[39] H. Yamawaki,et al. Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer , 2019, International journal of molecular sciences.
[40] C. Porta,et al. The adjuvant treatment of kidney cancer: a multidisciplinary outlook , 2019, Nature Reviews Nephrology.
[41] T. Kinoshita,et al. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review , 2019, International journal of molecular sciences.
[42] N. De Regge,et al. Porcine NK Cells Stimulate Proliferation of Pseudorabies Virus-Experienced CD8+ and CD4+CD8+ T Cells , 2019, Front. Immunol..
[43] J. Palefsky,et al. HPV-Associated Anal Cancer in the HIV/AIDS Patient. , 2018, Cancer treatment and research.
[44] R. Perez-soler,et al. Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence , 2018, Expert opinion on pharmacotherapy.
[45] M. Gertz,et al. Daratumumab for the treatment of AL amyloidosis , 2018, Leukemia & lymphoma.
[46] A. Jemal,et al. Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[47] Christiana Lucas,et al. An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. , 2019, Journal of infection and public health.
[48] A. Jeyasekharan,et al. ROS and the DNA damage response in cancer , 2018, Redox biology.
[49] M. Jolly,et al. Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities , 2018, Drugs.
[50] F. Cavalli,et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis , 2018, The Lancet. Oncology.
[51] L. Shan,et al. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. , 2018, Discovery medicine.
[52] Matthew M. Symer,et al. Recent advances in the management of anal cancer , 2018, F1000Research.
[53] D. Frezzetti,et al. Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer , 2018, Expert opinion on drug metabolism & toxicology.
[54] Carola Berking,et al. Melanoma , 2018, The Lancet.
[55] D. Davar,et al. MEK inhibitors for the treatment of NRAS mutant melanoma , 2018, Drug design, development and therapy.
[56] R. Burbano,et al. Molecular biology as a tool for the treatment of cancer , 2018, Clinical and Experimental Medicine.
[57] Yvonne E. Moussa,et al. The side effects of platinum-based chemotherapy drugs: a review for chemists. , 2018, Dalton transactions.
[58] F. Sclafani,et al. Systemic Therapies for Advanced Squamous Cell Anal Cancer , 2018, Current Oncology Reports.
[59] S. Asokan,et al. Pharmacological benefits of neferine ‐ A comprehensive review , 2018, Life sciences.
[60] R. Weiss. Metabolomics and Metabolic Reprogramming in Kidney Cancer. , 2018, Seminars in nephrology.
[61] Raju Dash,et al. Natural Products for the Management and Prevention of Breast Cancer , 2018, Evidence-based complementary and alternative medicine : eCAM.
[62] R. Hasina,et al. Genomics of mucoepidermoid and adenoid cystic carcinomas , 2018, Laryngoscope investigative otolaryngology.
[63] A. Čumová,et al. Natural compounds and combination therapy in colorectal cancer treatment. , 2018, European journal of medicinal chemistry.
[64] G. Bhagat,et al. BCL6 as a therapeutic target for lymphoma , 2018, Expert opinion on therapeutic targets.
[65] Yu-Ying He,et al. Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.
[66] G. Nasti,et al. Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. , 2017, Current cancer drug targets.
[67] Md Soriful Islam,et al. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics , 2018, Human reproduction update.
[68] A. Lenis,et al. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials , 2018, The Journal of urology.
[69] I. Durán,et al. Systemic treatment of renal cell cancer: A comprehensive review. , 2017, Cancer treatment reviews.
[70] M. McDonald,et al. Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease , 2017, Current Osteoporosis Reports.
[71] M. Morrison,et al. Oral Microbiome: A New Biomarker Reservoir for Oral and Oropharyngeal Cancers , 2017, Theranostics.
[72] Michael I. Seider,et al. Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. , 2017, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.
[73] E. Abdel-Sattar,et al. Chemical and Biological Investigation of Ochrosia elliptica Labill. Cultivated in Egypt , 2017 .
[74] Serguei A Castaneda,et al. Radiotherapy for Anal Cancer: Intensity-Modulated Radiotherapy and Future Directions. , 2017, Surgical oncology clinics of North America.
[75] Lovelace J. Luquette,et al. A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.
[76] S. Batra,et al. MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma , 2017, Expert opinion on therapeutic targets.
[77] M. Morris,et al. Simultaneous quantitation of abiraterone, enzalutamide, N‐desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS , 2017, Journal of pharmaceutical and biomedical analysis.
[78] N. Dawson,et al. Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. , 2017, American health & drug benefits.
[79] K. Flaherty,et al. Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.
[80] Baoan Chen,et al. β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect , 2017, Front. Pharmacol..
[81] J. Munkley. Glycosylation is a global target for androgen control in prostate cancer cells. , 2017, Endocrine-related cancer.
[82] Hong-Yo Kang,et al. MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer , 2017, International journal of molecular sciences.
[83] Walter J Curran,et al. Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.
[84] J. Cicenas,et al. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma , 2017, Medical Oncology.
[85] Ming Sun,et al. Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression , 2016, Oncotarget.
[86] F. Liu-Smith,et al. UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer. , 2017, Advances in experimental medicine and biology.
[87] A. Gratchev,et al. Tumor Associated Macrophages in Kidney Cancer , 2016, Analytical cellular pathology.
[88] A. Polizzi,et al. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies , 2016, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.
[89] Hui Liu,et al. International Journal of Molecular Sciences the Fascinating Effects of Baicalein on Cancer: a Review , 2022 .
[90] S. Vota,et al. Amyloidosis and its management: Amyloid neuropathies. , 2016, Current problems in cancer.
[91] W. Yarbrough,et al. Clinical and molecular insights into adenoid cystic carcinoma: Neural crest‐like stemness as a target , 2016, Laryngoscope investigative otolaryngology.
[92] R. Ferrarotto,et al. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma , 2016, Current opinion in oncology.
[93] Zongming Jiang,et al. Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ‐opioid receptor , 2016, International journal of cancer.
[94] C. Moskaluk,et al. Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials , 2015, Head & neck.
[95] C. Rasch,et al. Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. , 2016, European journal of cancer.
[96] B. Carneiro,et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling , 2015, Oncotarget.
[97] H. Ahmad,et al. Anticancer Effects of Extracts from the Fruit of Morinda Citrifolia (Noni) in Breast Cancer Cell Lines , 2015, Drug Research.
[98] S. Rosenberg,et al. Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.
[99] Kevin A. Henry,et al. Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.
[100] A. Colevas,et al. Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. , 2015, The oncologist.
[101] S. Oh,et al. Andrographolide and analogues in cancer prevention. , 2015, Frontiers in bioscience.
[102] K. Straif,et al. Betel quid chewing and the risk of oral and oropharyngeal cancers: A meta‐analysis with implications for cancer control , 2014, International journal of cancer.
[103] P. He,et al. 20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways , 2014, Tumor Biology.
[104] Y. Fukui. Mechanisms behind signet ring cell carcinoma formation. , 2014, Biochemical and biophysical research communications.
[105] Josias H. Hamman,et al. Review of Natural Compounds for Potential Skin Cancer Treatment , 2014, Molecules.
[106] T. Dorff,et al. Novel tyrosine kinase inhibitors for renal cell carcinoma , 2014, Expert review of clinical pharmacology.
[107] Corbin E. Meacham,et al. Tumour heterogeneity and cancer cell plasticity , 2013, Nature.
[108] V. Jordan,et al. Send Orders of Reprints at Reprints@benthamscience.net the Discovery and Development of Selective Estrogen Receptor Modulators (serms) for Clinical Practice the Biological Basis of Serm Action: Target Tissue Specific Actions , 2022 .
[109] L. Pusztai,et al. Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.
[110] Amy M. Pick,et al. Pazopanib for the treatment of metastatic renal cell carcinoma. , 2012, Clinical therapeutics.
[111] M. Gore,et al. Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. , 2012, European journal of cancer.
[112] A. Ravaud,et al. Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year , 2012, Current Urology Reports.
[113] Han Yong Choi,et al. The epidemiology of renal cell carcinoma. , 2011, European urology.
[114] David Needham,et al. Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. , 2011, The open nanomedicine journal.
[115] Rosette Lidereau,et al. Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway , 2010, PloS one.
[116] B. Moore,et al. Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. , 2010, Angewandte Chemie.
[117] R. Lothe,et al. DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset , 2010, PloS one.
[118] L. Standish,et al. Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells , 2010, Clinical Cancer Research.
[119] V. Vogel. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.
[120] M. D. De Bruin,et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. , 2008, Journal of the National Cancer Institute.
[121] R. Ganju,et al. Medicinal plants and cancer chemoprevention. , 2008, Current drug metabolism.
[122] M. Bremer,et al. Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial , 2008, Oncology.
[123] R. Salgia,et al. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion , 2007, British Journal of Cancer.
[124] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[125] Ram H Datar,et al. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[126] Ronald A. DePinho,et al. Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.
[127] M. Hussein. Ultraviolet radiation and skin cancer: molecular mechanisms , 2005, Journal of cutaneous pathology.
[128] V. Mazzaferro,et al. Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.
[129] M. Ellis,et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.
[130] D. Goodsell. The molecular perspective: tamoxifen and the estrogen receptor. , 2002, Stem cells.
[131] Z. Naito,et al. [Expression and intracytoplasmic signal transduction pathway of fibroblast growth factor (FGF)-10 in human cervical cancer cell lines]. , 2001, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.
[132] A. Arboix. [Cerebrovascular disease in the cancer patient]. , 2000, Revista de neurología (Ed. impresa).
[133] J. Posner,et al. Neurological complications of systemic cancer. , 1971, The Medical clinics of North America.
[134] J. Knowelden,et al. Cancer Epidemiology and Prevention , 1976, British Journal of Cancer.
[135] J. Haybittle,et al. Early breast cancer. , 1970, British medical journal.